BioCentury
ARTICLE | Clinical News

ACH-3102: Additional Phase IIa data

April 29, 2013 7:00 AM UTC

Data from all 8 treatment-naïve patients with HCV genotype 1b infection carrying the CC genotype of the interleukin-28B (IL-28B; IFNL3) gene in an open-label Phase IIa trial showed that oral ACH-3102 plus ribavirin for 12 weeks led to an SVR 4 weeks after the end of treatment in 5 patients. Achillion said 1 patient had a virologic relapse at week 15. Additionally, 6 patients achieved an RVR, defined as HCV RNA levels <25 IU/mL at week 4, and 6 patients achieved an ETR, defined as HCV RNA levels <25 IU/mL at week 12. ACH-3102 was well tolerated with no on-treatment virologic breakthroughs reported. Patients received 225 mg ACH-3102 on day 1 followed by 75 mg ACH-3102 once daily thereafter in combination with twice-daily ribavirin for 12 weeks. Achillion previously reported interim data from 5 evaluable patients in the trial (see BioCentury, Jan. 14). ...